Avia Pharma

PCP invests EUR 19 million in Avia Pharma to facilitate strategic acquisition P Capital Partners is excited to announce a strategic investment of EUR 19 million in Avia Pharma, a pharmaceutical company specializing in essential healthcare sectors. Founded in 2016, Avia Pharma is committed to enhancing individual well-being through products designed to improve the lives of people across all age groups and therapeutic areas. The company specializes in general OTC, Women’s Health, Urology, and Dermatology. The EUR 19 million funding is directed towards partially financing the acquisition of Neubourg, the German market leader in foam-based footcare, marking a significant expansion for Avia Pharma. Petra Elväng, Managing Director at PCP, commented; “We’re supporting the vision of co-founders Jacob Calmvik and Jostein Lønberg, who have remarkably propelled the company’s growth. We are very happy to continue our partnership with Avia Pharma in the next phase of their journey.” The partnership between PCP and Avia Pharma isn’t new; but began in 2022 when PCP supported Avia’s growth through a SEK 350 million term loan. This initial loan supported Avia’s acquisitions of three pharmaceutical portfolios/companies across Sweden, Finland, and Germany. aviapharma.com February, 2024